Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 234-241

  Rombouts, Yoann ^a   Ewing, Ewoud ^a   Van De Stadt, Lotte A ^b   Selman, Maurice H J ^a   Trouw, Leendert A ^a   Deelder, André M ^a   Huizinga, Tom W J ^a   Wuhrer, Manfred ^a   Van Schaardenburg, Dirkjan ^b,c   Toes, René E M ^a   Scherer, Hans U ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Reade   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FC RECEPTOR; GALACTOSE; GLYCOPEPTIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; TRYPSIN; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; FUCOSE; IMMUNOGLOBULIN FC FRAGMENT; POLYSACCHARIDE;

ADULT; ANTIBODY BLOOD LEVEL; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; FUCOSYLATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; RHEUMATOID ARTHRITIS; ARTHRITIS; CASE CONTROL STUDY; GLYCOSYLATION; IMMUNOLOGY; INFLAMMATION; METABOLISM; PRODROMAL SYMPTOM;

ADULT; ARTHRITIS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; FUCOSE; GALACTOSE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; INFLAMMATION; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PHENOTYPE; POLYSACCHARIDES; PRODROMAL SYMPTOMS;

EID: 84918590946     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203565     Document Type: Article

References (51)

1. Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-73.
2. Clavel C, Nogueira L, Laurent L, et al. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 2008;58:678-88.
3. Sokolove J, Zhao X, Chandra PE, et al. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum 2011;63:53-62.
4. Trouw LA, Haisma EM, Levarht EW, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 2009;60:1923-31.
5. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012;122:1791-802.
6. Nielen MM, Van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
7. Rantapaa-Dahlqvist S, De Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
8. Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2010;69:490-4.
9. Limper M, Van De Stadt L, Bos W, et al. The acute-phase response is not predictive for the development of arthritis in seropositive arthralgia-a prospective cohort study. J Rheumatol 2012;39:1914-17.
10. Van De Sande MG, De Hair MJ, Van Der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011;70:772-7.
11. Suwannalai P, Van De Stadt LA, Radner H, et al. Avidity maturation of ACPA in rheumatoid arthritis. Arthritis Rheum 2012;64:1323-8.
12. Van De Stadt LA, De Koning MH, Van De Stadt RJ, et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011;63:3226-33.
13. Van Der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010;69:1554-61.
14. Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008;58:3000-8.
15. Parekh RB, Dwek RA, Sutton BJ, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985;316:452-7.
16. Parekh R, Isenberg D, Rook G, et al. A comparative analysis of diseaseassociated changes in the galactosylation of serum IgG. J Autoimmun 1989;2:101-14.
17. Krapp S, Mimura Y, Jefferis R, et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003;325:979-89.
18. Yamaguchi Y, Nishimura M, Nagano M, et al. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta 2006;1760:693-700.
19. Jung ST, Reddy ST, Kang TH, et al. Aglycosylated IgG variants expressed in bacteria that selectively bind Fcgamma RI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci USA 2010;107:604-9.
20. Mimura Y, Church S, Ghirlando R, et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 2000;37:697-706.
21. Ferrara C, Grau S, Jager C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA 2011;108:12669-74.
22. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002;277:26733-40.
23. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-73.
24. Malhotra R, Wormald MR, Rudd PM, et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995;1:237-43.
25. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008;20:471-8.
26. Anthony RM, Kobayashi T, Wermeling F, et al. Intravenous gammaglobulin suppresses inflammation through a novel T (H) 2 pathway. Nature 2011;475:110-13.
27. Karsten CM, Pandey MK, Figge J, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fcgamma RIIB and dectin-1. Nat Med 2012;18:1401-6.
28. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313:670-3.
29. Van Zeben D, Rook GA, Hazes JM, et al. Early agalactosylation of IgG is associated with a more progressive disease course in patients with rheumatoid arthritis: results of a follow-up study. Br J Rheumatol 1994;33:36-43.
30. Lacki JK, Porawska W, Mackiewicz U, et al. Changes in agalactosyl IgG levels correlate with radiological progression in early rheumatoid arthritis. Ann Med 1996;28:265-9.
31. Gindzienska-Sieskiewicz E, Klimiuk PA, Kisiel DG, et al. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis. Clin Rheumatol 2007;26:685-90.
32. Croce A, Firuzi O, Altieri F, et al. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J Clin Lab Anal 2007;21:303-14.
33. Pasek M, Duk M, Podbielska M, et al. Galactosylation of IgG from rheumatoid arthritis (RA) patients-changes during therapy. Glycoconj J 2006;23:463-71.
34. Van Beneden K, Coppieters K, Laroy W, et al. Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis 2009;68:1360-5.
35. Rademacher TW, Williams P, Dwek RA. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci USA 1994;91:6123-7.
36. Scherer HU, Van Der Woude D, Ioan-Facsinay A, et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 2010;62:1620-9.
37. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
38. Selman MH, McDonnell LA, Palmblad M, et al. Immunoglobulin G glycopeptide profiling by matrix-assisted laser desorption ionization Fourier transform ion cyclotron resonance mass spectrometry. Anal Chem 2010;82:1073-81.
39. Scherer HU, Wang J, Toes RE, et al. Immunoglobulin 1 (IgG1) Fc-glycosylation profiling of anti-citrullinated peptide antibodies from human serum. Proteomics Clin Appl 2009;3:106-15.
40. Selman MH, Derks RJ, Bondt A, et al. Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface. J Proteomics 2012;75:1318-29.
41. Engelmann R, Brandt J, Eggert M, et al. IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA. Rheumatology (Oxford) 2008;47:1489-92.
42. Chapuy-Regaud S, Nogueira L, Clavel C, et al. IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin Exp Immunol 2005;139:542-50.
43. Wuhrer M, Porcelijn L, Kapur R, et al. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J Proteome Res 2009;8:450-6.
44. Siberil S, De Romeuf C, Bihoreau N, et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin Immunol 2006;118:170-9.
45. Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007;25:21-50.
46. Zauner G, Selman MH, Bondt A, et al. Glycoproteomic analysis of antibodies. Mol Cell Proteomics 2013;12:856-65.
47. Young A, Sumar N, Bodman K, et al. Agalactosyl IgG: an aid to differential diagnosis in early synovitis. Arthritis Rheum 1991;34:1425-9.
48. Ercan A, Cui J, Chatterton DE, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum 2010;62:2239-48.
49. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
50. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008;67:1488-92.
51. Wang J, Balog CI, Stavenhagen K, et al. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics 2011;10:M110.004655.